Manager TitleAgeSince
Chief Executive Officer 53 2022-08-29
Director of Finance/CFO 55 2023-05-01
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 2015-08-31
Chairman 71 2021-04-14
Director/Board Member 59 2021-04-14
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
+4.16%+3.42%+49.37%+94.17% 74.31B
-0.12%-4.46%+19.24%+73.35% 56.95B
+0.50%-0.92%+3.84%+34.87% 48.3B
-5.54%-4.34%+319.94%+681.19% 44.51B
-0.36%-1.71%+28.96%+33.10% 43.8B
+0.25%-1.19%+4.76%+107.57% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
-1.18%-3.27%-9.33%-14.27% 24.53B
Average +0.77%-0.15%+51.55%+122.37% 43.73B
Weighted average by Cap. +0.42%-0.46%+55.42%+130.79%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock